Welcome to our dedicated page for Harvard Biosci news (Ticker: HBIO), a resource for investors and traders seeking the latest updates and insights on Harvard Biosci stock.
Harvard Bioscience, Inc. (NASDAQ: HBIO) is a life science tools company that develops, manufactures and sells technologies, products and services used in research, drug and therapy discovery, bio‑production and preclinical testing. News about Harvard Bioscience often centers on how its laboratory instruments and platforms support life science applications for academic institutions, government laboratories, pharmaceutical companies, biotechnology firms and contract research organizations.
Investors and researchers following HBIO news will find regular updates on quarterly financial results, including revenues, gross margins, net income or loss, adjusted EBITDA and cash flows from operations, as reported in the company’s earnings press releases. These announcements are typically accompanied by guidance ranges for upcoming quarters and commentary on demand trends, backlog and operational discipline.
Harvard Bioscience news also covers capital structure and financing developments. In 2025, the company reported amendments to its existing credit agreement, discussions with lenders, and the execution of a new Loan and Security Agreement with BroadOak that introduced term loans and a convertible term loan, along with associated warrants and board nomination rights. These items appear in both press releases and Form 8‑K filings and are relevant to readers tracking the company’s liquidity, debt profile and going‑concern considerations.
Another theme in HBIO coverage is corporate governance and leadership changes. The company has announced a CEO succession plan, the appointment of new independent directors, and the designation of a lead independent director. Additional news items describe board appointments linked to financing arrangements and changes in audit committee composition. Operational news has included expanded distribution agreements for laboratory equipment with a major scientific supplier and references to technologies such as pumps, spectrophotometers, BTX electroporation systems and Mesh MEA organoid platforms.
For readers interested in HBIO, this news stream provides context on the company’s financial performance, governance, listing status on Nasdaq, and its role in supplying tools for life science research and preclinical testing. Regular updates can help observers understand how Harvard Bioscience is managing its business and capital structure while serving global life science customers.
Harvard Bioscience reported a 7% year-over-year revenue increase for Q1 2022, reaching $28.8 million, despite COVID-19 lockdowns in China affecting operations. Strong North American sales and demand for pre-clinical and cellular/molecular products were key drivers. However, the company faced an operating loss of $6.7 million, influenced by higher material costs and a $5 million legal accrual. Adjusted operating income fell to $2.4 million, with adjusted margins down to 8.2%. Looking ahead, the company expects annual revenue growth of 8% to 13%, alongside improving gross margins.
Harvard Bioscience (Nasdaq: HBIO) has launched SmartStudy™, a new feature for its Buxco® Inhalation System, enhancing precision and cost-efficiency in small animal research. This technology allows researchers to stop the delivery of test articles to individual subjects once the desired dosage is achieved, minimizing error and optimizing resource use. Demonstrations of SmartStudy™ occurred at the Society of Toxicology meeting and will continue at the American Thoracic Society conference. The innovation aims to significantly improve inhalation study methodologies.
Harvard Bioscience, Inc. (Nasdaq: HBIO) is set to announce its financial results for Q1 2022 on May 4, 2022, before market opening. A conference call to discuss these results will take place at 8:00 a.m. ET. Interested parties can join the call by calling toll-free 1 (877) 303-7611 or international 1 (970) 315-0445, using conference ID #6757353. The call will also be available via webcast on the company’s investor relations website.
Harvard Bioscience develops technologies for research and drug development, serving a wide range of clients globally.
Harvard Bioscience reported a 7% revenue increase year-over-year in Q4 2021, totaling $33.1 million, despite global supply chain challenges. Gross margin improved to 59%, fueled by a stronger product mix. Pre-clinical product revenue rose by 18% for the full year, while CMT products grew by 9% in Q4. However, operating income dipped to $1.7 million due to rising material and labor costs. The company anticipates 10-13% revenue growth for 2022, with plans for increased investment in sales and R&D.
Harvard Bioscience (Nasdaq: HBIO) is set to announce its fourth-quarter financial results for the period ending December 31, 2021, on March 8, 2022, prior to market opening. The company will hold a conference call at 8:00 a.m. Eastern Time to discuss these results. Investors can participate by dialing the provided numbers or via the live webcast accessible through their website. Harvard Bioscience specializes in developing technologies for fundamental research and drug development, serving various sectors from academia to pharmaceuticals.
Harvard Bioscience reported a 23% year-over-year revenue growth for Q3 2021, reaching $29.7 million, with pre-clinical product revenue up 28% and Cellular and Molecular Technologies (CMT) product revenue up 19%. Operating income showed a slight increase from $0.2 million to $0.5 million. Despite ongoing global supply chain disruptions impacting costs, adjusted operating margin remained solid at 13.3%. The company expects revenue growth of 15% to 17% for the year, up from previous estimates of 12% to 15%.
Harvard Bioscience (Nasdaq: HBIO) will announce its third-quarter financial results on November 3, 2021, prior to market opening. The announcement will be followed by a conference call at 8:00 a.m. Eastern Time to discuss the results. Interested parties can join the call by dialing 1 (877) 303-7611 (toll-free) or 1 (970) 315-0445 (international), using conference ID # 8391005. Additionally, a live webcast will be available on the company's website, where the earnings release and presentation will also be accessible.
Harvard Bioscience, Inc. (Nasdaq: HBIO) reported a 25% year-over-year revenue growth for Q2 2021, reaching $29.2 million, driven by strong demand in pre-clinical and Cellular and Molecular (CMT) products, which grew by 20% and 22%, respectively. Despite higher global supply chain costs affecting operating margins, adjusted operating margins remained robust at 14.6%. Looking ahead, the company anticipates a 12% to 15% revenue growth for the fiscal year. Operating income was impacted, showing a loss per share of $(0.01), with adjusted diluted EPS at $0.06.
Harvard Bioscience (Nasdaq: HBIO) will release its financial results for Q2 2021 on August 5, 2021, prior to market opening. The announcement will be followed by a conference call at 8:00 a.m. ET, accessible via toll-free number 1 (877) 303-7611 or international number 1 (970) 315-0445, with conference ID # 6293853. The call will also be webcast through the Harvard Bioscience website. The results and accompanying slide presentation will be available on the Investor Relations section of their site.
Harvard Bioscience (Nasdaq: HBIO) reported a revenue increase of 14% for Q1 2021, totaling $27 million, driven by strong pre-clinical product demand which rose 24%. This growth follows continued momentum from Q4 2020, aided by effective sales strategies and improved academic lab sales. The operating loss improved significantly, with adjusted operating income reaching $3.2 million and an adjusted operating margin of 12%. The company expects revenue growth of 10% to 14% for 2021, indicating a positive outlook for future business performance.